A share price of Cognition Therapeutics Inc [CGTX] is currently trading at $0.49, up 7.67%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The CGTX shares have gain 9.60% over the last week, with a monthly amount drifted -16.02%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Cognition Therapeutics Inc [NASDAQ: CGTX] stock has seen the most recent analyst activity on December 19, 2024, when B. Riley Securities upgraded its rating to a Buy and also boosted its price target to $1.50 from $1. Previously, Cantor Fitzgerald downgraded its rating to Neutral on July 30, 2024. On November 03, 2021, Oppenheimer initiated with a Outperform rating and assigned a price target of $22 on the stock. B. Riley Securities started tracking the stock assigning a Buy rating and suggested a price target of $27 on November 03, 2021.
Cognition Therapeutics Inc experienced fluctuations in its stock price throughout the past year between $0.34 and $2.95. Cognition Therapeutics Inc [NASDAQ: CGTX] shares were valued at $0.49 at the most recent close of the market.
Analyzing the CGTX fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -1.12, Equity is -1.6 and Total Capital is -2.83. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.04.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.4632 points at the first support level, and at 0.4366 for the second support level. However, for the 1st resistance point, the stock is sitting at 0.5032, and for the 2nd resistance point, it is at 0.5166.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Cognition Therapeutics Inc [NASDAQ:CGTX] is 2.65. As well, the Quick Ratio is 2.65, while the Cash Ratio is 2.24.
Transactions by insiders
Recent insider trading involved Ricciardi Lisa, CEO & President, that happened on Jan 31 ’25 when 38851.0 shares were purchased.
